Valuation: Control Bionics Limited

Market Cap 3.05Cr 2.12Cr 1.85Cr 1.71Cr 1.58Cr 3Cr 202.23Cr 20Cr 8.03Cr 100Cr 7.96Cr 7.79Cr 342.49Cr P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 3.02Cr 2.1Cr 1.84Cr 1.7Cr 1.57Cr 2.97Cr 200.66Cr 20Cr 7.96Cr 99Cr 7.9Cr 7.73Cr 339.83Cr EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
54.68%
Yield 2024 *
-
Yield 2025 -
1 day+2.74%
Current month+1.35%
1 month-17.58%
3 months+25.00%
6 months+27.12%
Current year+22.95%
1 week 0.07
Extreme 0.07
0.08
1 month 0.07
Extreme 0.07
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 01/12/2025
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%0.00%+78.57%-11.76% 2.09Cr
+3.73%+6.80%+9.75%-22.93% 1.73TCr
+3.87%-5.71%+14.03%+97.04% 168.39Cr
+4.76%+0.11%-39.78%-79.06% 124.58Cr
-2.75%-6.73%-32.28%+27.77% 106.09Cr
+2.92%-2.22%-29.25%-53.82% 63Cr
+3.91%-4.74%-39.86%-56.00% 55Cr
+2.60%+4.15%+35.25%-52.29% 47Cr
+1.13%-0.48%-54.86%-59.74% 38Cr
+2.67%-5.46%-24.37%-26.23% 34Cr
Average +2.56%-0.93%-8.28%-23.70% 236.65Cr
Weighted average by Cap. +3.41%+4.43%+2.40%-17.87%

Financials

2024 2025
Net sales 53.51L 37.22L 32.55L 30.03L 27.73L 52.62L 35Cr 3.59Cr 1.41Cr 17Cr 1.4Cr 1.37Cr 60Cr 61.45L 42.74L 37.39L 34.48L 31.85L 60.43L 41Cr 4.12Cr 1.62Cr 20Cr 1.6Cr 1.57Cr 69Cr
Net income -59.14L -41.13L -35.98L -33.19L -30.65L -58.16L -39Cr -3.97Cr -1.56Cr -19Cr -1.54Cr -1.51Cr -66Cr -61.09L -42.49L -37.17L -34.28L -31.66L -60.08L -41Cr -4.1Cr -1.61Cr -20Cr -1.6Cr -1.56Cr -69Cr
Net Debt -96.95T -67.43T -58.98T -54.4T -50.25T -95.34T -64.31L -7L -3L -31.68L -3L -2L -1.09Cr -2L -2L -1L -1L -1L -2L -1.57Cr -15.91L -6L -77.54L -6L -6L -2.67Cr
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
13/26/13 A$0.0750 +2.74% 1,57,186
10/26/10 A$0.0730 +4.29% 1,94,998
09/26/09 A$0.0700 -5.41% 80,523
08/26/08 A$0.0740 -1.33% 2,78,994
07/26/07 A$0.0750 0.00% 1,92,614

Annual profits - Rate of surprise